Hormone therapy in older women with breast cancer was associated with a reduced risk of subsequent dementia, a retrospective study of Medicare patients suggested. Breast cancer patients who received ...
Hormone modulating therapy (HMT) used for the treatment of breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias later in life, according to a new ...
Hormone modulating therapy (HMT) used for the treatment of breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias later in life, according to a new ...
(A) The AlphaFold protein structure of GPER from the public database (https://alphafold.com/entry/Q99527). (B) E2, the GPER-specific agonist G1, SERMs, and SERDs ...
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations ...
If you have metastatic breast cancer that’s hormone receptor-positive (HR+) and HER2-negative, your treatment plan looks very different from how it might have decades ago. Instead of relying on ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
The metastatic breast cancer (mBC) landscape is evolving rapidly due to the increasing prevalence of ESR1 mutations, a key driver for hormone receptor-positive (HR+) patients. ESR1 mutations, ...
Please provide your email address to receive an email when new articles are posted on . Lp(a) fluctuates throughout a woman’s lifetime. High levels are linked to adverse pregnancy outcomes. Data are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results